Categories: News

Option Care Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call

BANNOCKBURN, Ill., Jan. 21, 2026 (GLOBE NEWSWIRE) — Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced that the company will release results for its fourth quarter and full year 2025 on Tuesday, February 24, 2026 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day.

Conference Call Details
Participants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BIf3f7a42783bf4a85aae626ffa262fb95. The call can also be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

For Investor Inquiries:
Nicole Maggio
Senior Vice President, Corporate Controller
T: (312) 940-2495
Investor.relations@optioncare.com 

Staff

Recent Posts

University Medical Center Southern Nevada Becomes First Hospital in Nevada to Earn Magnet Recognition

Prestigious designation recognizes excellence in nursing, patient care, and clinical outcomesLAS VEGAS, Jan. 24, 2026…

17 minutes ago

Direct Meds NAD+ Injections Consumer Report 2026: Comparing Supplement and Peptide Alternatives, Dosage, Benefits & Side Effects

A consumer-focused examination of NAD+ injections, NAD+ supplements, NAD+ peptides, NAD+ dosage protocols, documented NAD+…

17 minutes ago

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today…

17 minutes ago

Nexalin Technology Receives Nasdaq Listing Status Notification

HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”…

17 minutes ago

MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity

TOKYO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President…

18 minutes ago